PRASUN JALAL to Retrospective Studies
This is a "connection" page, showing publications PRASUN JALAL has written about Retrospective Studies.
Connection Strength
0.236
-
Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes. Cancer Med. 2023 07; 12(14):15011-15025.
Score: 0.046
-
Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature. Rev Med Virol. 2022 11; 32(6):e2353.
Score: 0.043
-
Retrospective analysis of long-term outcome 10 years after liver transplantation for Wilson disease: experience over three decades. Transpl Int. 2020 08; 33(8):925-935.
Score: 0.038
-
The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure. J Hepatol. 2023 09; 79(3):717-727.
Score: 0.012
-
Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3).
Score: 0.011
-
Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. Liver Transpl. 2023 01 01; 29(1):15-25.
Score: 0.011
-
International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients. J Viral Hepat. 2022 09; 29(9):807-816.
Score: 0.011
-
Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. Clin Transplant. 2022 06; 36(6):e14646.
Score: 0.011
-
Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. Hepatology. 2021 12; 74(6):3316-3329.
Score: 0.010
-
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021 11; 75(5):1026-1033.
Score: 0.010
-
Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. Liver Transpl. 2020 01; 26(1):68-79.
Score: 0.009
-
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
Score: 0.009
-
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
Score: 0.009
-
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst. 2014 May 09; 106(5).
Score: 0.006